GlassScriptPhysician profile
Douglas J Renton
NPI 1972623577
$2,175.12
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $173 · 2021: $412 · 2022: $264 · 2023: $224 · 2024: $15.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $517.70 | 2019-2023 | Gattex |
| Abbvie INC. | $393.49 | 2019-2024 | |
| Boston Scientific Corporation | $260.83 | 2019-2023 | Exalt Model D |
| Janssen Biotech, INC. | $202.56 | 2019-2022 | |
| Merz North America, INC. | $83.48 | 2019 | |
| Melinta Therapeutics, LLC | $62.68 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Grifols USA, LLC | $60.32 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.22 | 2019 | |
| Celgene Corporation | $54.38 | 2021-2023 | Zeposia |
| Pfizer INC. | $50.75 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.40 | 2019 | |
| Amgen INC. | $48.67 | 2019-2023 | Tezspire |
| Lilly USA, LLC | $38.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.04 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $28.51 | 2019-2020 | |
| Qol Medical, LLC | $24.65 | 2019 | |
| Shire North American Group INC | $23.29 | 2019 | |
| Merck Sharp & Dohme LLC | $22.48 | 2019 | |
| Ucb, INC. | $22.26 | 2019 | |
| Genzyme Corporation | $19.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.40 | 2019 | |
| Horizon Therapeutics Plc | $18.02 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.95 | 2020 | |
| Mylan Specialty L.P. | $14.49 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Renton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.